Global Vaccine Centre GSK to Establish Global Vaccines R&D Centre in the US

Editor: Anke Geipel-Kern

GSK’s expands it global vaccines R&D footprint. A new hub is based in Rockville.

Related Companies

Headquarter of Glaxo Smith Kline in London.
Headquarter of Glaxo Smith Kline in London.
(Bild: GSK)

London, UK– GSK announced today it is further strengthening and expanding its vaccines presence in the US by establishing a new global centre for vaccines research and development (R&D) in Rockville, Maryland.

The site will become one of three global vaccines R&D centres for GSK, complementing the company’s existing global R&D centres in Rixensart, Belgium and in Siena, Italy, a site which GSK recently acquired from Novartis in March 2015.

The new US vaccines R&D centre will expand GSK’s efforts to discover and develop novel vaccines across a range of pressing public health threats, including those relevant to the US. It will consolidate vaccines R&D activities currently conducted at other GSK sites including in Philadelphia, PA and Cambridge, MA, into one centralised location. Key late stage development programmes, as well as vaccine discovery and new platform technology development will be led from Rockville.

The Rockville site, which was acquired by GSK in 2012, offers proximity to vaccines collaborators and key public health stakeholders. GSK anticipates site operations for vaccines to begin in Rockville as early as September 2015.

Luc Debruyne, President, GSK Vaccines, said: “As the global vaccines leader, GSK is on the cutting edge of vaccine development. Following the acquisition of Novartis’s global vaccines business and in recognition of the vaccines knowledge and expertise in the United States, we are pleased to expand our US presence with the creation of a world-class vaccines R&D centre. This will drive innovation, and enhance our capabilities for new vaccine discoveries that protect the US and public health around the world.”

(ID:43316758)